Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
AUSTIN, Texas, June 23, 2014 /PRNewswire/ -- XBiotech announced today that Gary Gonzales has joined the Company as Vice President of Clinical Operations. Mr. Gonzales will lead XBiotech's clinical trial team and manage the Company's international clinical operations.
Mr. Gonzales joins XBiotech from INC Research where he managed large, global pivotal phase III trials. Mr. Gonzales has B.S. & M.S. degrees in chemistry and biology and also holds a M.B.A. Mr. Gonzales comes to XBiotech with 20 years of industry experience with clinical operations and program management expertise and directly contributed to all stages of development for Lemtrada™ (alemtuzumab), a therapeutic monoclonal antibody.
Mr. Gonzales stated, "It is an exciting time to be working with monoclonal antibodies and XBiotech is on the cutting edge with its True Human™ molecule (Xilonix™). The Company is strategically positioned to make great strides in offering a treatment option for patients with colorectal cancer. I am thrilled to join the XBiotech team and look forward to applying my experience regarding monoclonal antibody development to usher Xilonix™ to regulatory approval."
John Simard, the Company's Chairman & CEO stated, "Mr. Gonzales is seasoned in all stages of drug development, from pre-clinical activities through market registration. We are delighted to have him join the team at this exciting juncture, including launch of our European Phase III registration program."
XBiotech is leading the commercialization of biological therapies-including the discovery and development of True Human™ antibodies. The Company's lead product candidate-in Phase III clinical studies-is a novel, breakthrough treatment for advanced colorectal cancer. XBiotech has also developed manufacturing technology to reduce infrastructure needs, lessen capital requirements and reduce lead times for biological drugs, ushering in a new era for cost and development efficiency in the biopharmaceutical industry.
©2012 PR Newswire. All Rights Reserved.